EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double‐blinded, randomized clinical trial in Sri Lanka

Pilana Vithanage Kalani Shihanika Hettiarachchi, Ruvini Manjula Hettiarachchi, Ruwan Duminda Jayasinghe, Mohaideen Sitheeque

Journal of Investigative and Clinical Dentistry · 2017-11 · 8 (4)

DOI: 10.1111/jicd.12237 ↗
AbstractBibliografische Angaben

Abstract

Abstract Aim Oral lichen planus ( OLP ) is a common, chronic inflammatory disease of the oral mucosa. Although several studies have shown the efficacy of different treatment modalities, a definitive cure has not yet been established. The present trial compares the effectiveness of topically‐applied clobetasol and tacrolimus in the symptomatic management of OLP . Methods A randomized, comparative, double‐blind study with 68 patients (43 females, 25 males; mean age: 46.76 years) was undertaken. Patients were randomly divided into two groups of 34 patients each to receive topical tacrolimus 0.1% cream or clobetasol propionate 0.05% cream for 3 weeks. Results After 3 weeks of treatment, the mean pain score dropped by 1.59 (right) and 1.53 (left) in the tacrolimus group, while in clobetasol group these values were 0.94 and 0.85, respectively. The mean scores for clinical appearance reduced by 1.18 (right) and 1.0 (left) in the tacrolimus group compared with a reduction of 0.5 and 0.26, respectively, in the clobetasol group. These reductions were statistically significant ( P < .05). Conclusion The results suggest that tacrolimus 0.1% cream is an effective alternative to topical steroid and can be considered a first‐line therapy in OLP . However, further studies are needed to confirm the effectiveness of this treatment before it is recommended for use in clinical practice.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →